Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Invivyd

< Previous 1 2 Next >
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
From Invivyd
Via GlobeNewswire
Tickers IVVD
FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
From Invivyd
Via GlobeNewswire
Tickers IVVD
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.